ASTRO Think Tank The Impact of Biomarkers and Nanotechnology on Radiation Oncology
June 15, 2018
ASTRO Headquarters, Arlington, Virginia
In recent years, major advancements in medical technology have created many new fields which provide unique opportunities for the field of radiation oncology to evolve and grow. ASTRO's first Think Tank, held at ASTRO Headquarters in Arlington, Va. on June 15, 2018, will address two of these new fields.
Genomic profiling, diagnostic mutation testing arrays, and the advent of so-called "liquid biopsies" have opened the floodgates to new and exciting information that could be pertinent to the research and practice of radiation oncology. The detection of biomarkers that may indicate radiosensitivity or radioresistance of either tumor or surrounding normal tissue can be hugely valuable when planning treatment or experiments. The impact of these biomarkers and how they can be integrated into research and practice will be discussed.
In addition, Nanomedicine has gone from a science-fiction trope to a real-world reality in a matter of years, and there are several pharmacologic and medical device companies using nanotechnology to create or deliver treatments to patients. The impacts of this burgeoning field and how it may affect radiation oncology will be discussed.
Nanomedicine and Radiation Oncology
- Liposomal Mitomycin C and Radiation
- Nanotherapeutics and Chemoradiation
- Nanoparticle Radiosensitizers
- Radiation Directed Drug Delivery
Biomarkers and Radiation Oncology
- Promises and Pitfalls of Genomic Profiling
- Diagnostic Assays for Radiotherapy Effectiveness
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells
